Synthetic Biologics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Synthetic Biologics, Inc.
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
MaaT Pharma’s replacement bacterial ecosystem for the gastro-intestinal tract, MaaT103, has shown promise in top-line data from a Phase II study in patients with refractory aGvHD, energizing the microbiome field.
Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.
Competing with several other firms to bring the first microbiome-derived therapy to market, Seres says the magnitude of its Phase III efficacy compared to placebo may enough for registrational filing.
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Adeona Pharmaceuticals, Inc.
- Pipex Pharmaceuticals, Inc.
- Sheffield Pharmaceuticals, Inc.